BP 897 is a potent (K i= 0.92 nM) dopamine D3 receptor compound developed for the treatment of cocaine abuse and craving. BP 897 has a high selectivity for the dopamine D3 versus D2 receptors (70‐fold) and a moderate affinity for 5‐HT1A receptors, (K

BP 897 is a potent (Ki= 0.92 nM) dopamine D3 receptor compound developed for the treatment of cocaine abuse and craving. BP 897 has a high selectivity for the dopamine D3 versus D2 receptors (70-fold) and a moderate affinity for 5-HT1A receptors, (Ki=

Increasing evidence suggests that enhanced dopamine (DA) neurotransmission in the nucleus accumbens (NAc) may play a role in mediating the reward and reinforcement produced by addictive drugs and in the attentional processing of drug-associated environmental